Umbilical cord mesenchymal stem cell (UC-MSC)

Umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent stromal cells derived from umbilical cord tissue, most commonly from the mucoid connective tissue known as Wharton's jelly. Unlike traditional molecular targets such as receptors or enzymes, UC-MSCs represent a living cell therapy modality that exerts therapeutic effects through complex, multi-pathway interactions with the host. Their primary biological role involves immunomodulation, where they secrete anti-inflammatory cytokines and growth factors to dampen pathological immune responses and facilitate endogenous tissue repair (Dominici et al., 2006, Cytotherapy). In clinical applications, UC-MSCs are utilized for their regenerative potential and their ability to treat conditions characterized by high inflammation or tissue damage, such as graft-versus-host disease (GVHD), rheumatoid arthritis, and myocardial infarction. They are particularly advantageous due to their non-invasive harvesting process, high proliferation rate, and low expression of major histocompatibility complex (MHC) class II molecules, which reduces the risk of immune rejection. While they are not a discrete molecular target, their therapeutic efficacy is often measured by their influence on various molecular pathways, including the inhibition of T-cell proliferation and the promotion of regulatory T-cell (Treg) formation.

Other names

Human umbilical cord mesenchymal stem cellshUC-MSCsWharton's jelly mesenchymal stem cellsWJ-MSCsUmbilical cord-derived mesenchymal stem cellsUC-MSCs

UC-MSCs function through the secretion of paracrine factors such as cytokines (IL-10, TGF-beta), growth factors (VEGF, HGF), and extracellular vesicles (exosomes) that modulate the local microenvironment. They also engage in direct cell-to-cell contact with immune cells (T-cells, B-cells, NK cells, and macrophages) to suppress inflammatory responses and promote tissue regeneration and angiogenesis (Wang et al., 2022, Stem Cell Res Ther).